NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.32 CHF | +1.97% |
|
+4.94% | +8.78% |
| 05-10 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
| 05-10 | Novartis Gets FDA Breakthrough Therapy Designation for Scemblix | DJ |
Presenter SpeechJoerg Reinhardt (Executives)[Interpreted] Ladies and gentlemen, good morning, ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
101.8
USD
Average target price
108.4
USD
Spread / Average Target
+6.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.78% | 208B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| -7.93% | 200B | |
| +7.68% | 166B | |
| -2.71% | 159B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Transcript : Novartis AG - Shareholder/Analyst Call
